Abstract:

A class of novel therapies leverages regenerative cell types in disease microenvironments.[1] This complex interplay challenges established good manufacturing practices, as standards and analytical tools to measure regenerative potency are missing.[2] That is, we can build the product right, but we do not know if we are building the right product. Here, we suggest that organ-chips, biomimetic in-vitro phenotyping platforms,[3,4] can serve as key quality assurance systems in regenerative medicine.[1,2,5]